Overall mean (SD) | Mild group mean (SD) | Severe group mean (SD) | |
n | 60 | 45 | 15 |
Age, years | 44.4 (11.7) | 42.8 (11.3) | 49.2 (12.0) |
BMI, kg/m2 | 29.3 (3.9) | 28.5 (3.5) | 32.0 (4.1) |
Epworth Sleepiness Scale (ESS), n/24 | 8.3 (4.3) | 8.0 (4.4) | 9.2 (4.1) |
Neck circumference, cm | 41.2 (3.4) | 40.2 (3.0) | 43.9 (3.3) |
Systolic blood pressure, mmHg | 125.8 (11.1) | 124.9 (11.6) | 128.6 (9.4) |
Diastolic blood pressure, mmHg | 81.6 (8.6) | 80.9 (9.0) | 83.7 (7.5) |
T90, min | 4.0 (9.6) | 1.0 (2.6) | 13.3 (15.6) |
T95, min | 92.1 (89.0) | 78.7 (89.0) | 132.2 (78.4) |
SpO2 nadir, % | 87.2 (5.7) | 88.6 (4.9) | 83.2 (6.1) |
AHI, events/hour | 19.1 (17.7) | 10.5 (4.9) | 44.9 (17.2) |
AHI (REM), events/hour | 20.3 (23.4) | 11.8 (10.5) | 45.6 (32.2) |
AHI (NREM), events/hour | 18.9 (17.7) | 10.3 (5.7) | 44.7 (16.6) |
ODI, events/hour | 14.3 (16.0) | 7.0 (5.0) | 36.0 (18.2) |
ArI, events/hour | 25.5 (13.9) | 20.3 (7.1) | 41 (17.7) |
Medications | n (%) | n (%) | n (%) |
Antidepressant (SSRI) | 7 (12) | 5 (11) | 2 (13) |
Antihypertensive | 5 (8) | 3 (7) | 2 (13) |
Antihypercholesterolaemic | 6 (10) | 4 (9) | 2 (13) |
Biometrics measured at the screening visit. Polysomnography variables measured during the placebo night. Medications subjectively reported via questionnaire during screening visit. Mild group: AHI at placebo visit < 20 events/hour; severe group: AHI at placebo visit ≥ 20 events/hour.
AHI, apnoea–hypopnoea index; Arl, arousal index; BMI, body mass index; N1, stage N1 sleep; N2, stage N2 sleep; NREM, non-rapid eye movement sleep; ODI, oxygen desaturation index; REM, rapid eye movement sleep; SE, sleep efficiency; SOL, sleep onset latency; SpO2nadir, oxygen saturation nadir; SWS, slow wave sleep; TST, total sleep time; WASO, wake after sleep onset.